Australian National Clinical Evidence Taskforce COVID-19 drug treatment guidelines: challenges of producing a living guideline

Title: Australian National Clinical Evidence Taskforce COVID-19 drug treatment guidelines: challenges of producing a living guideline
Creator: Barber, Bridget E.; White, Heath; Poole, Alexis P.; Davis, Joshua S.; McGloughlin, Steven A.; Turner, Tari
Relation: Medical Journal of Australia Vol. 219, Issue 5, p. 197-199
Publisher Link: http://dx.doi.org/10.5694/mja2.52044
Publisher: John Wiley & Sons
Resource Type: journal article
Date: 2023
Description: The National Clinical Evidence Taskforce (NCET) established coronavirus disease 2019 (COVID-19) drug treatment guidelines in March 2020 to provide clinicians with living evidence-based recommendations for the care of patients with COVID-19. These guidelines have been widely used and have informed practice in Australia and beyond. However, there are limitations to the available evidence, and, as the COVID-19 pandemic has progressed, the NCET has had to address a number of challenges. This perspective article discusses these limitations and challenges and the strategies developed to ensure that the guidelines remain relevant and useful for clinicians (Box).
Subject: COVID-19; guidelines as topic; National Clinical Evidence Taskforce (NCET); drug treatment; SDG 3; Sustainable Development Goals
Identifier: http://hdl.handle.net/1959.13/1487876
Identifier: uon:52283
Identifier: ISSN:0025-729X
Rights: x
Language: eng
Reviewed

Collections

Goal 3: Good Health and Well-Being

		Thumbnail	File	Description	Size	Format